Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
US Department of Justice
Chubb
Medtronic
Federal Trade Commission
Healthtrust
Harvard Business School
Cerilliant
US Army
AstraZeneca

Generated: October 21, 2017

DrugPatentWatch Database Preview

Forest Labs Company Profile

« Back to Dashboard

What is the competitive landscape for FOREST LABS, and what generic alternatives to FOREST LABS drugs are available?

FOREST LABS has forty-one approved drugs.

There are forty-eight US patents protecting FOREST LABS drugs and there have been seven Paragraph IV challenges on FOREST LABS drugs in the past three years.

There are four hundred and sixty-five patent family members on FOREST LABS drugs in fifty-two countries and twenty-two supplementary protection certificates in eleven countries.

Summary for Applicant: Forest Labs

International Patents:465
US Patents:48
Tradenames:40
Ingredients:27
NDAs:41
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Forest Labs Llc
LINZESS
linaclotide
CAPSULE;ORAL202811-001Aug 30, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Llc
LINZESS
linaclotide
CAPSULE;ORAL202811-001Aug 30, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-006Jul 13, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Forest Labs Llc
PYLERA
bismuth subcitrate potassium; metronidazole; tetracycline
CAPSULE;ORAL050786-001Sep 28, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Forest Labs Inc
ZENPEP
pancrelipase (amylase;lipase;protease)
CAPSULE, DELAYED RELEASE;ORAL022210-006Jul 13, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
LINZESS
linaclotide
CAPSULE;ORAL202811-003Jan 25, 2017RXYesNo► Subscribe► Subscribe► Subscribe
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Forest Labs Llc
VIIBRYD
vilazodone hydrochloride
TABLET;ORAL022567-003Jan 21, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Forest Labs

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-003Aug 14, 2002► Subscribe► Subscribe
Forest Labs Llc
PYLERA
bismuth subcitrate potassium; metronidazole; tetracycline
CAPSULE;ORAL050786-001Sep 28, 2006► Subscribe► Subscribe
Forest Labs Llc
NAMENDA XR
memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL022525-001Jun 21, 2010► Subscribe► Subscribe
Forest Labs Inc
URSO 250
ursodiol
TABLET;ORAL020675-001Dec 10, 1997► Subscribe► Subscribe
Forest Labs Inc
CARAFATE
sucralfate
TABLET;ORAL018333-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Forest Labs Llc
PYLERA
bismuth subcitrate potassium; metronidazole; tetracycline
CAPSULE;ORAL050786-001Sep 28, 2006► Subscribe► Subscribe
Forest Labs
LEXAPRO
escitalopram oxalate
TABLET;ORAL021323-001Aug 14, 2002► Subscribe► Subscribe
Forest Labs
BYSTOLIC
nebivolol hydrochloride
TABLET;ORAL021742-003Dec 17, 2007► Subscribe► Subscribe
Forest Labs Llc
NAMENDA
memantine hydrochloride
SOLUTION;ORAL021627-001Apr 18, 2005► Subscribe► Subscribe
Forest Labs Llc
NAMZARIC
donepezil hydrochloride; memantine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL206439-002Dec 23, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FOREST LABS drugs

Drugname Dosage Strength Tradename Submissiondate
levomilnacipran
Extended-release Capsules20 mg, 40 mg, 80 mg and 120 mg
FETZIMA 
7/25/2017
nebivolol hydrochloride and valsartan
Tablets5 mg/80 mg
BYVALSON
6/9/2017
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules7 mg/10 mg
NAMZARIC
9/26/2016
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules21 mg/10 mg
NAMZARIC
9/23/2016
linaclotide
Capsules145 mcg and 290 mcg
LINZESS
8/30/2016
memantine hydrochloride extended-release and donepezil hydrochloride
Capsules14 mg/10 mg and 28 mg/10 mg
NAMZARIC
5/18/2015
vilazodone hydrochloride
Tablets10 mg, 20 mg, and 40 mg
VIIBRYD
1/21/2015
bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
Capsules140 mg/125 mg/ 125 mg
PYLERA  
8/12/2014
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
8/16/2013
asenapine maleate
Sublingual Tablets5 mg and 10 mg
SAPHRIS
8/13/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg
NAMENDA XR
6/17/2013
memantine hydrochloride
Extended-release Capsules28 mg
NAMENDA XR
6/12/2013
memantine hydrochloride
Extended-release Capsules7 mg, 14 mg, 21 mg, and 28 mg
NAMENDA XR
6/10/2013
mesalamine
Suppository1000 mg
CANASA
5/24/2013
nebivolol hydrochloride
Tablets2.5 mg, 5 mg, 10 mg, and 20 mg
BYSTOLIC
12/19/2011
memantine hydrochloride
Tablets5 mg and 10 mg
NAMENDA
10/16/2007
escitalopram oxalate
Capsules5 mg
LEXAPRO
8/17/2005
escitalopram oxalate
Capsules10 mg and 20 mg
LEXAPRO
3/30/2005

Non-Orange Book Patents for Forest Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,293,229Methods of producing stable pancreatic enzyme compositions► Subscribe
2,012,058,182► Subscribe
9,624,204Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
8,921,375Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride► Subscribe
8,426,472Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
7,772,188Methods and compositions for the treatment of gastrointestinal disorders► Subscribe
2,014,073,571► Subscribe
8,927,552Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride► Subscribe
7,005,452Use of the dextrogyral enantiomer of milnacipran for the preparation of a drug► Subscribe
7,619,007Method and composition for administering an NMDA receptor antagonist to a subject► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Forest Labs Drugs

Country Document Number Estimated Expiration
Canada2784772► Subscribe
Singapore162734► Subscribe
Russian Federation2007140348► Subscribe
Canada2514948► Subscribe
China104053449► Subscribe
European Patent Office1594517► Subscribe
Russian Federation2445952► Subscribe
Australia2011218009► Subscribe
Cyprus1111058► Subscribe
European Patent Office1908461► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Forest Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/048United Kingdom► SubscribePRODUCT NAME: NEBIVOLOL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR HYDRATE; REGISTERED: NL RVG/19317 19951018; UK 00242/0309 19960509
02C/035Belgium► SubscribePRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
C/GB10/012United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0593Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
1998Austria► SubscribePRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
201Luxembourg► SubscribePRODUCT NAME: LINACLOTIDE ET TOUTE FORME THERAPEUTIQUE EQUIVALENTE DE CELUICI,PROTETE PAR LE BREVET DE BASE,Y COMPRIS DES SELS PHARMACEUTIQUEMENT ACCEPTABLES
00593Netherlands► SubscribePRODUCT NAME: LINACLOTIDE; REGISTRATION NO/DATE: EU/1/12/801/001-004 20121126
6Finland► Subscribe
C/GB02/046United Kingdom► SubscribePRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515
2013013Lithuania► SubscribePRODUCT NAME: LINACLOTIDUM; REGISTRATION NO/DATE: EU/1/12/801/001 - EU/1/12/801/004 20121126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cipla
Baxter
Queensland Health
Boehringer Ingelheim
AstraZeneca
Deloitte
Fish and Richardson
US Army
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot